Isomorphic Labs

Google DeepMind, Meta and Isomorphic Labs are contributing $300 million to accelerate research into virtual cells, computational models that simulate how cells behave. The funding is expected to advance AI-driven biology and drug discovery, with observers linking it to the rapid progress of AI models applied to genomic and cellular science.

The Chan Zuckerberg Biohub's Virtual Biology Initiative has secured $300 million in funding from Google, Meta, and Isomorphic Labs. The investment links major technology and AI drug-discovery companies to a push toward computational models of biological systems, underscoring growing tech-industry involvement in life science research.

Isomorphic Labs, the Alphabet-owned drug discovery company spun out of DeepMind, is reportedly in talks to raise new funding at a valuation of $40-50 billion. The company uses AI models, building on AlphaFold, to design new medicines and accelerate drug development. A round at that scale would place it among the most valuable AI-focused biotech firms, underscoring investor appetite for AI-driven pharmaceutical research.

Chan Zuckerberg Biohub has received $300 million from Google, Meta, and Isomorphic Labs to fund a virtual biology initiative. The investment will support AI-driven modeling and simulation of biological systems, combining the tech companies' computing expertise with the Biohub's biomedical research. The collaboration highlights growing tech-industry involvement in life sciences and drug discovery research.

Google DeepMind, Meta and AI drug discovery startup Isomorphic Labs are jointly investing $300 million in CZ Biohub, the nonprofit biomedical research organization co-founded by Mark Zuckerberg. The funding will support efforts to build a 'virtual cell' — an AI-driven model of cellular biology that could accelerate drug discovery and disease research.